±±¾©Ê¦·¶´óѧϸ°ûÉúÎïѧÊÔÌâÀúÄê»ã×Ü£¨²©Ê¿£©2001Äê-1990Äê(ȱ1997Äê,1998Äê) +*]$PVAFA
Ò»¡¢ Ãû´Ê½âÊÍ£º %
/VCjuV
1£® ͬԴºÐ£¨homeobox£©£¨96¡¢99¡¢91£© <m]0!ii
2£® PCR£¨96£© i}
sAF/
3£® ·ºËØ£¨ubquitin£©£¨96£© ,,gMUpL7_8
4£® °é·Ö×Ó£¨chapron£©£¨96£© b0{i +R
5£® ת¼Òò×Ó£¨trascription factor£©£¨96£© P 0,]`w
6£® DG£IP3£¨96£© hul,Yd) Z
7£® »ùÒòÇóý£*****ene knock out£©£¨96¡¢00£© J rx^
8£® ΢¹Ü×éÖ¯ÖÐÐÄ£¨MTOC£©£¨96¡¢01£© j Q5 F}
9£® ¶ËÁ£Ã¸£¨telomerase£©£¨96£© ?e$&=FC0;
10£® µ°°×·ÖÑ¡£¨protein sorting£©£¨96¡¢99¡¢00£© )4L2&e`k)(
11£® Transformation£¨92£© -G~]e6:zD
12£® TransfectionתȾ£¨92£© ny5P*yWEh
13£® Transcytosis×ªÒÆ×÷Óã¨92£© 5H0qMt P
14£® Transductionתµ¼£¨92£© :>0ywg
15£® Transdetermination£¨92£© @N4_){s*
16£® Transdifferentiation£¨92£© gwoe1:F:J
17£® Transgenic animalת»ùÒò¶¯Î92£© .~f )4'T 9
18£® Rb£1£¨92£© Vp/XVyL}R
19£® P53£¨92¡¢91£© EZ)b E9
20£® C£jun£¨92£© Qn*l,Z]US
21£® ΢¹Û½áºÏµ°°×MAPS£¨99¡¢91£© 7g\v (P
22£® °ûÄÚÌ壨99£© }?s-$@$R
23£® Cyclin dependent kinase inhibitor(CDKI)(99) >n"0>[:4
24£® G£protein£¨91£© ys9:";X;}
25£® Restriction point£¨91£© F1#{(uW
26£® Antipost£¨91£© 0;bdwIP3
27£® Capping£¨91£© }dkXRce*
28£® TATAbox£¨91£© wpK1nA+7N
29£® cDNA library£¨90£© ?^Rp"
H
30£® Aritotic apparatus£¨90£© z%8`F%2
31£® ¿çĤÐźŠtransmembrane signal£¨90£© Nny*C`uDF
32£® ´ÙÓÐË¿·ÖÁÑÔ mitogen£¨90£© MB)<@.A0
33£® Nuclear lamina£¨90£© 4 Ej->T.
34£® ϸ°ûµòÍö£¨apotosis£©£¨00£© n
_K1%
35£® ϸ°ûÍâ»ùÖÊ£¨00¡¢01£© IuXgxR%
36£® ϸ°û·Ö»¯£¨00£© QX=T
uyO
37£® ϸ°ûÐźÅתµ¼£¨signal transduction£©£¨00£© Cqr{Nssu
38£® ¿Ë¡£¨00£© 32ki ?\
P
39£® »ùÒò×飨00£© wA5Iz{uQO
40£® Caspase£¨00£© $JY\q2
41£® ת¼Òò×Ó£¨00£© [G}dPXD
42£® ÅßÌ¥¸Éϸ°û£¨01£© Kv@P Uzu
43£® ¼¤¹â¹²¾Û½¹ÏÔ΢¾µ£¨01£© <x}wy+SG
44£® DNAоƬ£¨01£© %~Yo{4mHs
¶þ¡¢ ÎÊ´ðÌ⣺ AU9C#;JD
1£® ÊÔÊöÀÒ°±Ëáµ°°×¼¤Ã¸ÊÜÌåµÄÐźÅͨ·£¨96£© ^#R`Uptib
2£® ÊÔ¾ÙÀý˵Ã÷ÐÅʹϵͳÖÐÓëϸ°ûÔöÖ³Óйصļ¤Ã¸¼°Æä¹¦ÄÜ£¨95£© b}qfOgd5
3£® ÊÔ·ÖÎöÐźÅתµ¼£¨transduction£©µÄ¼¸Ìõͨ·µÄ¹²ÐÔÓëÌØÐÔ£¨92£© y0xBNhev
4£® µ°°×ÖʵÄÁ×ËữÓëÈ¥Á×ËữÔÚϸ°ûÐźÅϵͳ´«µ¼ÖеÄ×÷Óã¨93¡¢99£© ~5P9^`KNH
5£® ÊÔÊöÁ×õ¥Ë®½âøC£¨PLC£©µÄ·ÖÀ༰ÔÚϸ°ûÐźÅתµ¼ÖеÄ×÷Óᣣ¨01£© v`|]57?A
6£® ÊÔÊöϸ°û½ÓÊÜ»¯Ñ§Ðźźóµ÷½Ú»ùÒò±í´ïµÄ;¾¶£¨94£© al[^pPKZ
7£® ÊÔÊöϸ°ûÖÜÆÚ¸÷½×¶ÎÖÐCyclins£CdksµÄµ÷¿Ø×÷Óã¨96£© Mq0MtC6-
8£® ¾ÙÀý˵Ã÷CKIÔÚϸ°ûÔöÖ³µ÷¿ØÖеÄ×÷Óã¨96£© KU8,8:yY
9£® ÏêÊöcyclins£cdksϵͳÔÚϸ°ûÖÜÆÚG2/M¼°M/G1¹ý¶ÈÖÐÈçºÎÊܵ½µ÷¿ØµÄ£¿ÒÑÖªÄÇЩ·Ö×Ó¿ÉÄÜÊÇcdksµÄµ×Îï¼°ÆäÔÚÁ×ËữÓëÈ¥Á×Ëữ¹ý³ÌÖжÔϸ°û½á¹¹Ó빦Äܱ仯µÄÓ°Ï죨95£©
ljbAfd
10£® Cdc2ºÍcyclin»ùÒò£¨cdc13£©ÈçºÎµ÷¿ØÏ¸°ûÖÜÆÚÔËתµÄÏÖ´ú¸ÅÄ92¡¢94£© 9k6s
11£® Ϊʲô˵µ°°×ÖÊÁ×Ëữ£È¥Á×ËữºÍ·ºËؽ鵼µÄµ°°×ÖÊË®½â£¨UPP£©µÄ»¥Ïàе÷ÍÆ¶¯Ï¸°ûÖÜÆÚµÄÔËת£¿£¨01£© HyzSHI
12£® ϸ°ûÔöÖ³µ÷¿ØµÄ·Ö×Ó»úÖÆ£¨00£© T1Py6Q,-
13£® ϸ°û¹Ç¼ÜÔÚϸ°ûÔöÖ³ÖÜÆÚÖеÄ×÷Óã¨00£© 2K:A4)jZ
14£® P34cdc2µÄÐÔÖʼ°Æä×÷Óõ×ÎïÊÇʲô£¿½«ÒýÆðºÎÖÖЧӦ£¿£¨91£© beOMln+R
15£® ϸ°ûÓÐË¿·ÖÁÑÖзĴ¸Ìå΢¹ÜµÄ¶¯Á¦Ñ§±ä»¯»úÀí¼°ÆäÓëȾɫÌåÔ˶¯µÄ¹ØÏµ£¨95£© >w.;A%|N
16£® ΢¹ÜµÄ×é×°ÓëÈ¥×é×°ÔÚϸ°ûÓÐË¿·ÖÁѹý³ÌÖеĶ¯Ì¬±ä»¯¼°Æä×÷Óã¨92£© /r7xA}se^
17£® ϸ°ûÓÐË¿·ÖÁѹý³ÌÖзĴ¸ÌåµÄ×é×°ÓëÈ¥×é×°µÄ¶¯Ì¬±ä»¯¼°Æä¹¦ÄÜ£¨93£© y.Z_\@
18£® ϸ°ûÓÐË¿·ÖÁѺóÆÚȾɫÌå·ÖÀëÇ÷ÏòÁ½¼«µÄ»úÀíÊÇÈçºÎÖ¤Ã÷µÄ£¿£¨90£© nD5wN~[J
19£® ÊÔÊöÖÐÐÄÁ£/¶¯Á£È¥ÔÚϸ°ûÓÐË¿·ÖÁÑÖеÄ×÷Óã¨99£© -E}X`?WhD
20£® KinetochoreÊÇÓÉÄļ¸ÖÖÖ÷Òªµ°°××é³É£¬ÓÃʲô·½·¨Ñо¿Æä¶¨Î»¡¢·Ö×ÓÁ¿¼°»úÄÜ£¿£¨90£© ta?NO{*
21£® ÊÔ·Ö±ðÐðÊöÈËÀà×ÅË¿Á£ºÍ¶¯Á£µÄ»ù±¾×é³É¼«ÆäĿǰËùÖªµÄ¹¦ÄÜ£¨01£© ()aCE^C
22£® ÊÔÊöϸ°û±à³ÌÐÔËÀÍö£¨programmed cell death£©ºÍϸ°ûµòÍö£¨apoptosis£©µÄÌØÕ÷ºÍÉúÀíѧÒâÒå¼°Æä¿ÉÄܵĻùÒòµ÷¿Ø£¬ÄãÈÏΪÑо¿µÄÖØµãÓ¦·ÅÔں䦣¿ÎªÊ²Ã´£¿£¨95£© ;.4y@?B
23£® ApoptosisÓëneerosisµÄ¼ì²âÓëÇø±ð£¨99£© q(n"r0)=
24£® ÈçºÎ¼ø±ðϸ°ûµòÍöÓ뻵ËÀ¡£Ï¸°ûµòÍöÑо¿µÄÖØÒªÒâÒåÊÇʲô£¿£¨01£© ST{Vi';}
25£® ÊÔÊöunipintin£proteasen proteolytic system£¨99£© l,o'J%<%
26£® ÒÑÖªÓÐÄÇЩÖ÷ÒªµÄ°©»ùÒòÓëÒÖ°©»ùÒòÓëϸ°ûÖÜÆÚµÄµ÷¿ØÓйأ¿²¢¾ÙÀý˵Ã÷£¨93£© iZNS? ^U
27£® Oncogene¼°Æä²úÎïÓëϸ°ûÔöÖ³µÄ¹ØÏµ£¨91£© :)lS9<Y}
28£® ¾ÙÀý˵Ã÷oncogene¡¢growth factors¼°ÊÜÌåÖ®¼äµÄÁªÏµ£¨90£© 6xDk3
29£® ÊÔÊöºáÎÆ¼¡¡¢Ï¸°ûÄÚ´Öϸ˿Á½·Ö×ӵĽṹ¡¢¸÷ÖÖÖ÷Òªµ°°×³É·ÖÔÚ¼¡ÈâÊÕËõÖеÄ×÷Óᣣ¨90£© |:C0_`M9
30£® ÊÔÊöϸ°ûÖÊÃþÉÏĤµ°°×µÄ¼¸ÖÖÀàÐͼ°Æä¹¦ÄÜ£¨95£© RI*n]HNgy+
31£® ÊÔÊöÃâÒßѧ¼¼ÊõÔÚϸ°ûÉúÎïѧÑо¿ÖеÄÓ¦Óã¨92£© ]njNSn
32£® ͬԴºÐµÄ·¢ÏÖ¼°ÆäÔÚÉúÎïÖеÄÖØÒªÒâÒ壨92£© u[**,.Ecg
33£® ÈçÒÑ֪ijһ»ùÒòƬ¶ÎÐòÁкÍÒÑ»ñµÃijһµ¥¿Ë¡¿¹ÌåÓ¦ÓúÎÖÖ¼¼Êõ·Ïߵõ½ËüµÄcDNA¿Ë¡£¨94£© EK# 11@0%
34£® ¾ÙÀý˵Ã÷ÃâÒßÓ«¹âFISH¡¢ÃâÒߵ羵ÖîÏî¼¼ÊõµÄ»ù±¾ÔÀí¼°ÆäÔÚϸ°ûÉúÎïѧÑо¿Öеĸ÷½â¾öʲôÎÊÌ⣨94£© QD7KE6KP'
35£® ÄãµÄ˶ʿÂÛÎÄÌá³öÁËʲôÎÊÌ⣿ÈçºÎ½â¾öµÄ£¿½áÂÛÊÇʲô£¿£¨96¡¢94¡¢00£©